We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01668719
Recruitment Status : Recruiting
First Posted : August 20, 2012
Last Update Posted : July 13, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 2018
  Estimated Study Completion Date : September 2021